OTCPK:ASAB

Stock Analysis Report

Executive Summary

Stragenics, Inc. operates recreational cannabis consumer Websites.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Risks

  • Stragenics has significant price volatility in the past 3 months.
  • Stragenics's last earnings update was 1211 days ago.
  • Stragenics is not covered by any analysts.

Share Price & News

How has Stragenics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

ASAB

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

-99.0%

ASAB

9.9%

US Medical Equipment

1.6%

US Market

ASAB underperformed the Medical Equipment industry which returned 20.1% over the past year.

ASAB underperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

ASABIndustryMarket
7 Day0%0.5%-0.02%
30 Day-99.0%0.09%2.7%
90 Day-99.0%2.0%1.4%
1 Year-99.0%-99.0%10.8%9.9%3.8%1.6%
3 Yearn/a69.0%63.9%45.2%35.8%
5 Year-100.0%-100.0%136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is Stragenics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Stragenics undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Stragenics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Stragenics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of ASAB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Stragenics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Stragenics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Stragenics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of ASAB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Stragenics's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Stragenics performed over the past 5 years?

0.2%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Stragenics has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

  • When a company lacks a financial track record, its management’s track record becomes important. Corporate governance also plays an important role in a young business as board members are seen as highly-experienced leaders to help steer the company into the future. Take a look at Stragenics's' management and board experience and expertise to assess their ability to deliver on their strategic promises.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Stragenics's filings and announcements here.
  • Explore strong past performing companies in the Healthcare industry.

Financial Health

How is Stragenics's financial position?


In this section we usually analyse Stragenics's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Stragenics has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of ASAB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Stragenics's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Stragenics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Stragenics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Stragenics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Stragenics has not reported any payouts.

Unable to verify if Stragenics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Stragenics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Stragenics's salary, the management and board of directors tenure and is there insider trading?


CEO

Alan Grofe (73yo)

5yrs

Tenure

0

Mr. Alan W. Grofe has been the Chief Executive Officer, President, Secretary and Treasurer of Stragenics, Inc. since March 06, 2014. Mr. Grofe has been Chief Executive Officer of Allerayde SAB Limited sinc ...


CEO Compensation Analysis

Insufficient data for Alan to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.

Insufficient data for Alan to compare compensation growth.


Insider Trading

No 3 month insider trading information.


Management Team

  • Alan Grofe (73yo)

    CEO, President

    • Tenure: 5yrs

Board Members

  • Alan Grofe (73yo)

    CEO, President

    • Tenure: 5yrs

Company Information

Stragenics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Stragenics, Inc.
  • Ticker: ASAB
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$424.000
  • Shares outstanding: 424.94m
  • Website: https://www.stragenics.com

Number of Employees


Location

  • Stragenics, Inc.
  • 100 Rialto Place
  • Suite 700
  • Melbourne
  • Florida
  • 32901
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ASABOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 2010

Biography

Stragenics, Inc. operates recreational cannabis consumer Websites. Its Websites provide product information, dispensary information and locations, news, strain reviews, and resources for marijuana legal st ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/03/19 00:30
End of Day Share Price2019/03/06 00:00
Earnings2015/09/30
Annual Earnings2014/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.